Despite evidence suggesting that BCMA expression is lower in plasma cells derived from AL amyloidosis compared to MM [50,52], this did not appear to negatively impact the therapeutic efficacy of BCMA-targeted CAR-T therapy. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.